

.BOSSPATIENTEDUCATIONTEACH

HEADER/NOTE SUBJECT: Ambulatory Bispecific Antibody ONN Education Session

Bispecific Therapy: (Pick One)

Teclistimab

Talquetemab

Elrantamab

A teaching session was held with @NAME@ and @HIS@ caregiver *name* *relationship* to review education in preparation for bispecific antibody therapy in detail. We followed along in the Bispecific Antibody Education Booklet. We discussed that for the first 7-10 days during the dose escalation phase, the patient must have constant caregiver(s).

Caregiver(s) must

- be in your home or residence 24 hours a day for the first 10 days to help watch for side effects.
- be sure that your bispecific wallet card is always with you.
- drive you to and from clinic visits in a reliable car.
- learn to take your blood pressure, pulse, oxygen saturation, (also known as vital signs) and a perform simple neurologic check (this includes alertness, thinking, speaking, balance, and related nervous system abilities).
- write all vital signs and comments on the worksheets three times a day: morning, afternoon, evening.
- attend daily phone appointments with you and your cancer care team.
- report all side effects to the care team during appointments.

I described the expected patient and caregiver experience on a day-to-day basis using a calendar with all the anticipated appointments listed. We discussed potential side effects of therapy, as well as parameters to call @HIS@ the oncology care team. We reviewed the potential that the patient may need to be admitted cytokine release syndrome.

The patient and caregiver was provided with a sample of the Bispecific Antibody Patient Wallet Card and reviewed in detail the symptoms or any changes in @HIS@ health, including any of the following symptoms that @HIS@ and/or @HIS@ family would immediately contact their oncologist or seek immediate medical attention after the bispecific antibody is infused.

We reviewed the Contacts & When to Call section of the booklet. Specifically, when to call for non-urgent symptoms during operating business hours, and how to contact their myeloma clinical care team via page operator for urgent questions and/or during evenings and weekends. We also reviewed when to call 911 and to have the ambulance go to BWH Emergency Department for any urgent symptoms.

Following the instructions outlined in detail in the Bispecifics Booklet, we reviewed how to monitor blood pressure, pulse, temperature, oxygen level, and complete a neurotoxicity check. The patient and caregiver demonstrated competency in monitoring for symptoms using these tools.

The patient and caregiver were reminded to bring their booklet and equipment kit to their C1D1 visit, and continue to bring their booklet to every visit for review with their clinical care team.

The patient and caregiver have been referred to our resource specialist for assistance. @NAME@ and their caregiver verbalized understanding of the bispecific antibody therapy process and what to expect during the ambulatory dose escalation phase of care.

The patient and caregiver had time to ask questions, which I answered to the best of my ability. The patient and caregiver verbalized understanding of the education provided as documented above, as well as how and when to contact their clinical care team.

“Patient verbalized acknowledgement and agrees that this home monitoring equipment is NOT warranted by DFCI against possible malfunction or need of repair and accepts the equipment “AS IS”. The patient fully releases and discharges DFCI from any and all claims or liability due to any malfunction or disrepair of the loaned home monitoring equipment. This means that the patient will not sue DFCI or try to hold DFCI legally or financially responsible for any harm or injury that might relate to use of the loaned home monitoring equipment.”

@SIGNATURE@

How to create a speed button:

<https://dfcipolicies.ellucid.com/documents/view/8672/active>